SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 356-366

  Niemi, Mikko ^a   Pasanen, Marja K ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; ORGANIC ANION TRANSPORTER 2; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL MEMBRANE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DIFFUSION; DRUG PENETRATION; DRUG UPTAKE; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIPOPHILICITY; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC; PRAVASTATIN; PROSPECTIVE STUDIES; REFERENCE VALUES; SEX CHARACTERISTICS; SEX FACTORS;

EID: 33749049136     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.06.010     Document Type: Article

References (46)

1. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19 (2005) 117-125
2. Singhvi S.M., Pan H.Y., Morrison R.A., and Willard D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 29 (1990) 239-243
3. Fischer V., Johanson L., Heitz F., Tullman R., Graham E., Baldeck J.P., et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 27 (1999) 410-416
4. Neuvonen P.J., Kantola T., and Kivistö K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63 (1998) 332-341
5. Kivistö K.T., Kantola T., and Neuvonen P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 46 (1998) 49-53
6. Kantola T., Backman J.T., Niemi M., Kivistö K.T., and Neuvonen P.J. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 56 (2000) 225-229
7. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 (1999) 413-428
8. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274 (1999) 37161-37168
9. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297 (2001) 861-867
10. Kopplow K., Letschert K., König J., Walter B., and Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 68 (2005) 1031-1038
11. Kim R.B. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?. Clin Pharmacol Ther 75 (2004) 381-385
12. Ho R.H., and Kim R.B. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78 (2005) 260-277
13. Tirona R.G., Leake B.F., Merino G., and Kim R.B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276 (2001) 35669-35675
14. Niemi M., Schaeffeler E., Lang T., Fromm M.F., Neuvonen M., Kyrklund C., et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14 (2004) 429-440
15. Tirona R.G., Leake B.F., Wolkoff A.W., and Kim R.B. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304 (2003) 223-228
16. Nozawa T., Minami H., Sugiura S., Tsuji A., and Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33 (2005) 434-439
17. Kameyama Y., Yamashita K., Kobayashi K., Hosokawa M., and Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15 (2005) 513-522
18. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 73 (2003) 554-565
19. Mwinyi J., Johne A., Bauer S., Roots I., and Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 75 (2004) 415-421
20. Niemi M., Neuvonen P.J., Hofmann U., Backman J.T., Schwab M., Lütjohann D., et al. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenet Genomics 15 (2005) 303-309
21. Matsushima S., Maeda K., Kondo C., Hirano M., Sasaki M., Suzuki H., et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314 (2005) 1059-1067
22. Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, et al. Association of genetic polymorphism in ABCC2 with hepatic MRP2 expression and pravastatin pharmacokinetics. Pharmacogenet Genomics. In press 2006.
23. Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I., et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 74 (2003) 186-194
24. Pasanen M.K., Backman J.T., Neuvonen P.J., and Niemi M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol 62 (2006) 409-415
25. Stephens M., Smith N.J., and Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68 (2001) 978-989
26. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 (2003) 1162-1169
27. fastPHASE: software for haplotype reconstruction, and estimating missing genotypes from population data. Available from URL:http://www.stat.washington.edu/stephens/software.html. Accessed Sept 11, 2006.
28. Mulvana D., Jemal M., and Pulver S.C. Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS. J Pharm Biomed Anal 23 (2000) 851-866
29. Hallynck T.H., Soep H.H., Thomis J.A., Boelaert J., Daneels R., and Dettli L. Should clearance be normalised to body surface or to lean body mass?. Br J Clin Pharmacol 11 (1981) 523-526
30. Hagenbuch B., and Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 447 (2004) 653-665
31. Klein C.E., Gupta E., Reid J.M., Atherton P.J., Sloan J.A., Pitot H.C., et al. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 72 (2002) 638-647
32. Prewett E.J., Smith J.T., Nwokolo C.U., Sawyerr A.M., and Pounder R.E. Twenty-four hour intragastric acidity and plasma gastrin concentration profiles in female and male subjects. Clin Sci (Lond) 80 (1991) 619-624
33. Everett D.W., Chando T.J., Didonato G.C., Singhvi S.M., Pan H.Y., and Weinstein S.H. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19 (1991) 740-748
34. Gandhi M., Aweeka F., Greenblatt R.M., and Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44 (2004) 499-523
35. Tachibana-Iimori R., Tabara Y., Kusuhara H., Kohara K., Kawamoto R., Nakura J., et al. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab Pharmacokinet 19 (2004) 375-380
36. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
37. Morimoto K., Ueda S., Seki N., Igawa Y., Kameyama Y., Shimizu A., et al. OATP-C (OATP1B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients [abstract]. Clin Pharmacol Ther 77 (2005) P21
38. Nozawa T., Nakajima M., Tamai I., Noda K., Nezu J., Sai Y., et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 302 (2002) 804-813
39. Lee E., Ryan S., Birmingham B., Zalikowski J., March R., Ambrose H., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
40. Niemi M., Backman J.T., Kajosaari L.I., Leathart J.B., Neuvonen M., Daly A.K., et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77 (2005) 468-478
41. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75 (2004) 455-463
42. Hirano M., Maeda K., Shitara Y., and Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311 (2004) 139-146
43. Kajosaari L.I., Niemi M., Neuvonen M., Laitila J., Neuvonen P.J., and Backman J.T. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78 (2005) 388-399
44. Shitara Y., Itoh T., Sato H., Li A.P., and Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304 (2003) 610-616
45. Shitara Y., Hirano M., Sato H., and Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311 (2004) 228-236
46. Chung J.Y., Cho J.Y., Yu K.S., Kim J.R., Oh D.S., Jung H.R., et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78 (2005) 342-350